Risk of skin cancer in patients with vitiligo

Patients with vitiligo have a decreased risk of melanoma and non-melanoma skin cancer, a study suggests

Vitiligo: Patients may have a lower risk of skin cancer (Photograph: John F Wilson MD/SPL)
Vitiligo: Patients may have a lower risk of skin cancer (Photograph: John F Wilson MD/SPL)

Researchers found that patients with vitiligo had a three times lower chance of developing melanoma and non-melanoma skin cancer compared with patients without the condition. They also found that in patients treated with phototherapy, the risk was not increased.

The retrospective, comparative cohort study, which took place in the Netherlands, asked patients with non-segmental vitilgo aged 50 years or over to take part in a postal survey.

The survey asked questions on vitiligo characteristics, history of phototherapy and skin cancer history. The patients' partners were asked to fill in a control questionnaire. A total of 2,635 invitations were sent out and 1,307 eligible questionnaires were used in the analysis.

Teulings HE, Overkamp M, Ceylan E et al. Br J Dermatol 2013; 168: 162-71

Want news like this straight to your inbox?
Sign up for our bulletins

Read these next

1.5 CPD credits: Managing the psychosocial impact of vitiligo

1.5 CPD credits: Managing the psychosocial impact of vitiligo

Vitiligo is not curable and has significant psychosocial...

Facial segmental vitiligo

The distribution of segmental vitiligo on the face...

Identifying disorders in skin pigmentation

Identifying disorders in skin pigmentation

Pigmentation disorders encompass an array of conditions.



Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more